Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.55 |
| ▸ | PPARG | P37231 | 10/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16289560 | 1.00 | PPARA (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL5351802 | 0.94 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL316084 | 0.94 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL13489723 | 0.94 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL432222 | 0.94 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2541324 | 0.94 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL10692756 | 0.88 | PPARA (0.50) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL22636121 | 0.88 | CYP1A2 (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL22636123 | 0.88 | CYP1A2 (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL22381014 | 0.88 | PPARA (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20100221749-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | UNIVERSITE DE ROUEN | 2010-09-02 | — | — | US | disclosed |
| US-20100221749-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | UNIVERSITE DE ROUEN | 2010-09-02 | — | — | US | disclosed |
| US-4414149-A | POLYPEPTIDE | ARMOUR PHARMACEUTICAL COMPANY (US) | 1983-11-08 | — | — | US | disclosed |
| US-4401593-A | CYCLIC POLYPEPTIDES | ARMOUR PHARMACEUTICAL COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
| US-4397780-A | SUBSTITUTION ALALOGS OF NATURAL CALCITONINS | ARMOUR PHARMACEUTICAL COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
| US-4391747-A | CALCITONIN PEPTIDES | ARMOUR PHARMACEUTICAL COMPANY (US) | 1983-07-05 | — | — | US | disclosed |
| US-4388235-A | SYNTHETIC CALCITONIN | ARMOUR PHARMACEUTICAL COMPANY (US) | 1983-06-14 | — | — | US | disclosed |
| US-4304692-A | RESIN PEPTIDE FOR MAKING CALCITONIN ANALOGUES | ARMOUR PHARMACEUTICAL COMPANY (US) | 1981-12-08 | — | — | US | disclosed |
| US-4239680-A | CALCITONIN ACITIVITY | ARMOUR AND COMPANY (US) | 1980-12-16 | — | — | US | disclosed |
| US-4217268-A | CALCITONINS | RHONE-POULENC RORER PHARMACEUTICALS INC. | 1980-08-12 | — | — | US | disclosed |
| US-4212795-A | TO FORM DISULFIDE BOND | ARMOUR PHARMACEUTICAL COMPANY (US) | 1980-07-15 | — | — | US | disclosed |
| US-4062815-A | DIVINYLBENZENE CROSSLINKED POLYSTYRENE | ARMOUR PHARMACEUTICAL COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | PPARA 3215/4885PPARG 3973/4885PPARD 3438/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | PPARA 3215/4885PPARG 3973/4885PPARD 3438/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | PPARA 3215/4885PPARG 3973/4885PPARD 3438/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | PPARA 3215/4885PPARG 3973/4885PPARD 3438/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | PPARA 3215/4885PPARG 3973/4885PPARD 3438/4885 |
| US-20100221749-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | DNPEP, PEPD, LNPEP | PPARA 4436/4885PPARG 4419/4885PPARD 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.